Cme Group Inc. CME

Revenue Intelligence Report • 70 quarters of SEC filing data • Updated 2026-03-15

Revenue is driven by efficient SG&A spend, with every $1 of SG&A generating $2.53 of long-run revenue, indicating strong cost leverage underpinning topline growth. The model is linear and well-validated, with a 5.8% MAPE and a holdout test that predicted $1.6B versus actual $1.6B (0.5% error). Latest quarterly revenue was $1.649B, and the FY forecast is $6.9B, up 6.4% year over year. The ongoing SG&A ROI supports a constructive outlook with stable, mid-single-digit top-line growth and durable revenue expansion.

Investment Thesis

The econometric model achieves strong accuracy (5.8% MAPE), suggesting Cme Group Inc.'s revenue trajectory is well-characterized by its spending patterns. Each $1 of SG&A spending generates $2.53 in revenue, reflecting strong commercial efficiency.

Next FY Revenue
$6.94B
+6.4% YoY
SG&A Multiplier
$2.53 per $1
Model Accuracy
5.8% MAPE
Holdout validation: The model predicted $1.6B vs the actual $1.6B — an error of 0.5%.
Note: Cme Group Inc. does not report R&D expenses separately. This analysis uses SG&A spending only.

Revenue Forecast

CME Revenue Forecast

Quarterly Detail

QuarterModel ForecastActual95% RangeYoY GrowthStatus
Q4 2025 $1.6B $1.6B $1.5B – $1.8B +7.5% ✓ In range
Q2 2026 $1.8B $1.5B – $2.0B +6.7%
Q3 2026 $1.7B $1.4B – $2.0B +1.7%
Q4 2026 $1.7B $1.4B – $2.0B +10.4%
Q1 2027 $1.8B $1.4B – $2.1B +7.4%

How Spending Drives Revenue

CME Spending Timing
Reading this chart: Each line shows the cumulative revenue generated per $1 spent over subsequent quarters. The effect builds over 4-5 quarters as investments mature.

Want this analysis for your portfolio?

I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.

Get in Touch